Browsing: drugs

GLP-1 medications such as Ozempic have transformed the treatment of Type 2 diabetes, helping millions of patients better control their blood sugar while reducing cardiovascular risk and, for many, promoting substantial weight loss

Mich. (News 10) – GLP-1 weight loss drugs have grown sharply in popularity in recent years, but health experts are warning users about the challenges that can follow when patients stop taking them

Celltrion (068270.KS) is set to unveil preclinical results for its next-generation obesity treatment and early clinical data for antibody-drug conjugate (ADC) candidates in succession, bringing its new drug development progress into full view. The company aims to cultivate new drugs as a fresh growth pillar, drawing on the cash-generating power and research, development and commercialization…

Glucagon-like peptide-1 (GLP-1) receptor agonist obesity drugs such as Wegovy and Mounjaro have opened a new paradigm in obesity care with their remarkable weight-loss effects and ability to improve complications. The problem is that patients who actually need pharmacological treatment are not receiving it properly. Experts point out that institutional reforms are needed to support…

Four years ago, journalist and political strategist Jasmyne Cannick wasn’t chasing the latest GLP-1 weight-loss trend. She was trying to avoid diabetes

A meta-analysis of the weight loss effectiveness of GLP-1 drugs found that tirzepatide (marketed as Zepbound for weight loss) and Mounjaro (marketed for treatment of Type 2 diabetes) helped patients lose more than 20% of their starting body weight

As the use of glucagon-like peptide-1 (GLP-1) class obesity treatments such as Wegovy and Mounjaro increases, reports of side effects are drawing attention. A wide range of issues is being reported, from the well-known gastrointestinal problems to hair loss

Weight-loss drugs in the glucagon-like peptide-1 (GLP-1) class, such as Wegovy and Mounjaro, are being analyzed for their impact not only on body weight but also on psychological changes that can influence human relationships

SEATTLE —The use of weight-loss drugs like Ozempic or Wegovy has ballooned over the past few years, with one in eight American adults currently taking a GLP-1 medication for weight loss or to manage conditions such as diabetes or heart disease, according to a poll conducted by KFF. Yet for millions of Medicare beneficiaries, these…

People taking popular GLP-1 medications such as Ozempic, Wegovy and Mounjaro may face a higher risk of hair loss than patients using other diabetes drugs, according to a new study published in The British Medical Journal